 Eligible patients will be randomized to receive antifungal treatment with anidulafungin or placebo. Following enrollment, study treatment or placebo will be started as soon as possible. When the Candida or yeast organisms have been speciated andor a susceptibility profile is known, the study medication will be adjusted based on susceptibility patterns. The investigators propose to treat with antifungal therapy for a total of 14 days. 